Sarepta announces FDA Advisory Committee meeting for SRP-9001 on May 12

Sarepta Therapeutics announced that the date of the U.S. Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee meeting for the SRP-9001 biologics license application is May 12, 2023. The advisory committee meeting will be hosted as a virtual meeting. SRP-9001 is Sarepta’s investigational gene therapy for the treatment of Duchenne muscular dystrophy.